Journal article
Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models
E Lopez de Maturana, A Picornell, A Masson-Lecomte, M Kogevinas, M Marquez, A Carrato, A Tardon, J Lloreta, M Garcia-Closas, D Silverman, N Rothman, S Chanock, FX Real, ME Goddard, N Malats
BMC Cancer | BMC | Published : 2016
Abstract
BACKGROUND: We adapted Bayesian statistical learning strategies to the prognosis field to investigate if genome-wide common SNP improve the prediction ability of clinico-pathological prognosticators and applied it to non-muscle invasive bladder cancer (NMIBC) patients. METHODS: Adapted Bayesian sequential threshold models in combination with LASSO were applied to consider the time-to-event and the censoring nature of data. We studied 822 NMIBC patients followed-up >10 years. The study outcomes were time-to-first-recurrence and time-to-progression. The predictive ability of the models including up to 171,304 SNP and/or 6 clinico-pathological prognosticators was evaluated using AUC-ROC and det..
View full abstractGrants
Awarded by Red Tematica de Investigacion Cooperativa en Cancer
Awarded by Instituto de Salud Carlos III
Awarded by Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, USA
Awarded by EU-7FP-HEALTH-TransBioBC
Awarded by European Urological Scholarship Program for Research (EUSP Scholarship)
Funding Acknowledgements
The work was partially supported by Red Tematica de Investigacion Cooperativa en Cancer (#RD12/0036/0050), Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, (Grant numbers #PI00-0745, #PI05-1436, and #PI06-1614), and Asociacion Espanola Contra el Cancer (AECC), Spain; the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, USA (Contract NCI NO2-CP-11015); and EU-FP7-HEALTH-F2-2008-201663-UROMOL and EU-7FP-HEALTH-TransBioBC #601933. ELM was funded by a Sara Borrell fellowship, Instituto de Salud Carlos III, Spain; and AML by a fellowship of the European Urological Scholarship Program for Research (EUSP Scholarship S-01-2013).